Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.

Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, Franczak MB, Goveas JS, Li SJ.

Neuroimage. 2012 Apr 2;60(2):1083-91. doi: 10.1016/j.neuroimage.2011.12.077. Epub 2012 Jan 8.

2.

Efficacy of a high dosage of donepezil for Alzheimer's disease as examined by single-photon emission computed tomography imaging.

Kanaya K, Abe S, Sakai M, Fujii H, Koizumi K, Iwamoto T.

Psychogeriatrics. 2012 Sep;12(3):172-8. doi: 10.1111/j.1479-8301.2011.00399.x. Erratum in: Psychogeriatrics. 2012 Dec;12(4):263. Abe, Shine [added]; Sakai, Minoru [added]; Fujii, Hiroko [added]; Koizumi, Kiyoshi [added]; Iwamoto, Toshihiko [added].

3.

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.

Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R.

BMC Geriatr. 2013 Jun 6;13:56. doi: 10.1186/1471-2318-13-56.

4.
5.

Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer's disease by using an automated program, 3DSRT.

Tateno M, Kobayashi S, Utsumi K, Morii H, Fujii K.

Neuroradiology. 2008 Aug;50(8):723-7. doi: 10.1007/s00234-008-0401-y. Epub 2008 May 16.

PMID:
18483726
6.

The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.

Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E.

J Neurol Sci. 2012 Nov 15;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003. Epub 2012 Sep 7.

PMID:
22959283
7.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
8.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
9.

Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease.

Yoshida T, Ha-Kawa S, Yoshimura M, Nobuhara K, Kinoshita T, Sawada S.

Ann Nucl Med. 2007 Jul;21(5):257-65. Epub 2007 Jul 25.

PMID:
17634843
10.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT.

Neurology. 1998 Jan;50(1):136-45.

PMID:
9443470
11.

Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.

Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2008;26(3):203-11. doi: 10.1159/000152911. Epub 2008 Sep 4.

PMID:
18769065
12.

Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients.

Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, Pupi A, Rodriguez G.

Clin Neurophysiol. 2002 Aug;113(8):1241-8.

PMID:
12140003
13.

Quantitative assessment of cerebral hemodynamic parameters by QUASAR arterial spin labeling in Alzheimer's disease and cognitively normal Elderly adults at 3-tesla.

Mak HK, Chan Q, Zhang Z, Petersen ET, Qiu D, Zhang L, Yau KK, Chu LW, Golay X.

J Alzheimers Dis. 2012;31(1):33-44. doi: 10.3233/JAD-2012-111877.

PMID:
22504315
14.

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.

Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. Epub 2009 Jan 28.

PMID:
19176895
15.

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.

Frölich L, Ashwood T, Nilsson J, Eckerwall G; Sirocco Investigators.

J Alzheimers Dis. 2011;24(2):363-74. doi: 10.3233/JAD-2011-101554.

PMID:
21258153
16.

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators.

Alzheimers Dement. 2008 Mar;4(2):145-53. doi: 10.1016/j.jalz.2008.02.001.

PMID:
18631958
17.

Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI.

Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M, Jones JL, Antuono PG, Li SJ.

J Magn Reson Imaging. 2011 Oct;34(4):764-73. doi: 10.1002/jmri.22662. Epub 2011 Jul 18.

18.

Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.

Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, Pupi A, Robert PH, Rodriguez G, Darcourt J.

J Nucl Med. 2002 Aug;43(8):983-90.

19.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
20.

Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.

Yatabe Y, Hashimoto M, Kaneda K, Honda K, Ogawa Y, Yuuki S, Ikeda M.

Psychogeriatrics. 2013 Jun;13(2):88-93. doi: 10.1111/psyg.12004.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk